Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Streptococcus pneumoniae type 15B capsular polysaccharide diphtheria CRM197 protein conjugate antigen
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
Streptococcus pneumoniae type 15B capsular polysaccharide diphtheria CRM197 protein conjugate antigen is a component of certain pneumococcal conjugate vaccines. It consists of the purified capsular polysaccharide from Streptococcus pneumoniae serotype 15B, chemically linked (conjugated) to a nontoxic variant of diphtheria toxin known as CRM197. This conjugation enhances immunogenicity by inducing a T-cell dependent immune response, leading to improved antibody production and immunological memory compared to unconjugated (polysaccharide-only) vaccines[1][3][8]. The primary indication is for active immunization against invasive pneumococcal disease and pneumonia caused by S. pneumoniae serotype 15B[2][5]. This antigen may be included in multivalent pneumococcal vaccines such as PCV20 or PCV21, which are designed for broader protection against multiple S. pneumoniae serotypes[5][8].
- Other names
- Streptococcus pneumoniae serotype 15B polysaccharide conjugateStreptococcus pneumoniae type 15B capsular polysaccharide antigen
02
Targets
BCR-Spn15B (B-cell receptor specific for Streptococcus pneumoniae type 15B capsular polysaccharide)MHC II (Major histocompatibility complex class II receptor)15B CPS (Streptococcus pneumoniae serotype 15B capsular polysaccharide)
Beyond the preview
Go deeper on Streptococcus pneumoniae type 15B capsular polysaccharide diphtheria CRM197 protein conjugate antigen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Streptococcus pneumoniae type 15B capsular polysaccharide diphtheria CRM197 protein conjugate antigen.